Related Experiment Video

Updated: Jul 3, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

An update on the medical therapy of advanced metastatic renal cell carcinoma

Stephan Kruck1, Axel S Merseburger, Georgios Gakis

  • 1Department of Urology, Eberhard-Karls-University, Tuebingen, Germany.

Scandinavian Journal of Urology and Nephrology
|July 11, 2008
PubMed

Insights

Multikinase inhibitors like sorafenib and sunitinib show promise in treating metastatic renal cell carcinoma (RCC), improving response rates and progression-free survival compared to older therapies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (RCC) presents a significant clinical challenge.
  • Cytokine-based therapies have historically been used but with limited efficacy.
  • Novel targeted therapies are needed for improved patient outcomes.

Purpose of the Study:

  • To review the effectiveness of multikinase inhibitors in first- and second-line therapy for metastatic renal cell carcinoma (RCC).
  • To compare the efficacy of these novel agents against traditional cytokine-based treatments.

Main Methods:

  • Review of clinical studies evaluating multikinase inhibitors in metastatic RCC.
  • Analysis of data on response rate and progression-free survival.
  • Focus on agents targeting vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) pathways, as well as mTOR inhibitors.

Main Results:

  • Multikinase inhibitors demonstrated increased response rates in metastatic RCC patients.
  • Prolonged progression-free survival was observed with these agents compared to cytokine therapies.
  • Specific inhibitors like sorafenib, sunitinib, and temsirolimus show significant activity.

Conclusions:

  • Multikinase inhibitors represent a more effective treatment strategy for metastatic renal cell carcinoma.
  • Targeted therapies offer improved outcomes, particularly for patients with poor prognosis.
  • Further clinical data supports the use of these agents in systemic RCC treatment.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...